Heidelberg

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Amyloidosis3 trials
• Chronic kidney disease1 trial
• High blood pressure1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial
• Withdrawn1 trial

Lead sponsor

• Alnylam Pharmaceuticals4 trials
• Dicerna Pharmaceuticals, Inc., a Novo Nordisk company1 trial

Running trials

• Recruiting

  DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

  NCT07358078· Alnylam Pharmaceuticals· Source

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• High blood pressure1 recruiting

Closed trials

• Recruiting

  Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

  NCT04580420· Phase 2· Dicerna Pharmaceuticals, Inc., a Novo Nordisk company· Source

  Contact: Novo Nordisk

• Completed

  HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379· Phase 3· Alnylam Pharmaceuticals· Source